盐酸兰地洛尔(Landiolol Hydrochloride) - 药物靶点：β1-adrenergic receptor_在研适应症：室上性心动过速，心律失常，心房颤动_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Landiolol、Landiolol hydrochloride (JAN)、ONO 1101 hydrochloride

+ [9]

靶点

β1-adrenergic receptor

作用机制

β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)

治疗领域

心血管疾病

在研适应症

室上性心动过速心律失常心房颤动+ [4]

非在研适应症

冠心病

原研机构

Ono Pharmaceutical Co., Ltd.

在研机构

南京海辰药业股份有限公司

Ono Pharmaceutical Co., Ltd.Trimedica Ltd.

+ [1]

非在研机构

Aop Orphan Pharmaceuticals GmbH

最高研发阶段批准上市

首次获批日期

日本 (2002-07-05),

心房颤动心房扑动窦性心动过速+ [2]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C25H40ClN3O8

InChIKeyDLPGJHSONYLBKP-IKGOIYPNSA-N

CAS号144481-98-1

关联

71

项与盐酸兰地洛尔相关的临床试验

NCT04931225 / Recruiting临床3期IIT

LANdiolol MIcrocirculatory Effects During Septic chOc

The objectives of this study are to evaluate the effect of continuous intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours ) up to a 15% decrease in Heart Rate (HR) on microcirculatory vascular reactivity vs. usual tachycardia management and evaluate the hemodynamic effects of Landiolol vs. usual management in patients with septic shock.

开始日期2022-07-18

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT05084118 / Recruiting临床3期IIT

A Prospective, Randomized, Double- Blind, Placebo- Controlled Study to Evaluate the Efficacy of Landiolol Hydrochloride for Prevention of Atrial Fibrillation in Patients Undergoing Cardiac Surgery

Postoperative atrial fibrillation (POAF) is the most common arrhythmia after cardiac surgery with incidences ranging from 20% to 40% with the consequence of increasing mortality, morbidity, and hospital length of stay, as well as increasing the costs to the health care system. To prevent POAF the use of beta-blockers is suggested by the EACTA and ESC guidelines. Despite the prophylactic use, the discontinuation of beta-blockers in the perioperative period is a known risk factor that contributes to the occurrence of POAF. Due to the short half time and the highly beta-1-selective properties of Landiolol, it could be possible to initiate a betablocker for prevention in the immediate postoperative setting, without adverse effects like hypotension or severe bradycardia as seen with other betablockers like Metoprolol or even sometimes Esmolol.
Landiolol is already approved for the treatment of atrial tachycardias but is not yet approved for the use of prevention of POAF. In multiple previous studies the preventive potential of Landiolol in cardiac surgery could be proven in japanese study populations, with limitations due to limited sample sizes. In these trials the use of low-dose Landiolol effectively reduced the incidence of POAF without significant differences of increased side effects or in the hemodynamic stability compared to the placebo or standard of care groups.
The primary objective of this prospective, double-blind, randomized, placebo-controlled phase III trial is to prove that the postoperative application of low-dose Landiolol significantly reduces the incidence of POAF without increased adverse events or hemodynamic instability compared to the placebo group after cardiac surgery in a non-Asian population.

开始日期2021-10-21

申办/合作机构

Medical University of Vienna

NCT05554978 / Recruiting临床1/2期IIT

Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest: a Randomized, Double-blind, Placebo-controlled, Pilot Trial

This study investigates the efficacy of landiolol versus placebo in patients with out-of-hospital cardiac arrest (OHCA) and refractory ventricular fibrillation (electrical storm).

开始日期2021-03-03

申办/合作机构

Medical University of Vienna

100 项与盐酸兰地洛尔相关的临床结果

登录后查看更多信息

100 项与盐酸兰地洛尔相关的转化医学

登录后查看更多信息

100 项与盐酸兰地洛尔相关的专利（医药）

登录后查看更多信息

429

项与盐酸兰地洛尔相关的文献（医药）

2024-09-19·INTENSIVE CARE MEDICINE

Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP).

Article

作者: Trimmel, Helmut ; Unger, Martin ; Klade, Christoph ; Černý, Vladimír ; Schober, Andreas ; Fuchs, Christian ; Joannidis, Michael ; Frank, Sandra ; Podbregar, Matej ; Krejcy, Kurt ; Siebers, Christian ; Morelli, Andrea ; Tamme, Kadri ; Pretsch, Ingrid ; Sus, Jan ; Dostál, Pavel ; Biancofiore, Gianni ; Duliczki, Éva ; Cihlář, Radek ; Duška, František ; Pernerstorfer, Thomas ; Borgstedt, Rainer ; Krumpl, Günther ; Rehberg, Sebastian ; Guarracino, Fabio ; Kirchbaumer-Baroian, Nairi ; Rahmel, Tim

PURPOSE:

Excessive tachycardia in resuscitated septic shock patients can impair hemodynamics and worsen patient outcome. We investigated whether heart rate (HR) control can be achieved without increased vasopressor requirements using the titratable highly selective, ultra-short-acting β1-blocker landiolol.

METHODS:

This randomized, open-label, controlled trial was conducted at 20 sites in 7 European countries from 2018 to 2022 and investigated the efficacy and safety of landiolol in adult patients with septic shock and persistent tachycardia. Patients were randomly assigned to receive either landiolol along with standard treatment (n = 99) or standard treatment alone (n = 101). The combined primary endpoint was HR response (i.e., HR within the range of 80-94 beats per minute) and its maintenance without increasing vasopressor requirements during the first 24 h after treatment start. Key secondary endpoints were 28-day mortality and adverse events.

RESULTS:

Out of 196 included septic shock patients, 98 received standard treatment combined with landiolol and 98 standard treatment alone. A significantly larger proportion of patients met the combined primary endpoint in the landiolol group than in the control group (39.8% [39/98] vs. 23.5% [23/98]), with a between-group difference of 16.5% (95% confidence interval [CI]: 3.4-28.8%; p = 0.013). There were no statistically significant differences between study groups in tested secondary outcomes and adverse events.

CONCLUSION:

The ultra-short-acting beta-blocker landiolol was effective in reducing and maintaining HR without increasing vasopressor requirements after 24 h in patients with septic shock and persistent tachycardia. There were no differences in adverse events and clinical outcomes such as 28-day mortality vs. standard of care. The results of this study, in the context of previous trials, do not support a treatment strategy of stringent HR reduction (< 95 bpm) in an unselected septic shock population with persistent tachycardia. Further investigations are needed to identify septic shock patient phenotypes that benefit clinically from HR control.

2024-09-17·ACS Omega

Identification of Potential Tryptase Inhibitors from FDA-Approved Drugs Using Machine Learning, Molecular Docking, and Experimental Validation

Article

作者: Han, Eun-Taek ; Yasir, Muhammad ; Park, Jinyoung ; Han, Jin-Hee ; Chun, Wanjoo ; Park, Won Sun

This study explores the innovative use of machine learning (ML) to identify novel tryptase inhibitors from a library of FDA-approved drugs, with subsequent confirmation via molecular docking and experimental validation. Tryptase, a significant mediator in inflammatory and allergic responses, presents a therapeutic target for various inflammatory diseases. However, the development of effective tryptase inhibitors has been challenging due to the enzyme's complex activation and regulation mechanisms. Utilizing a machine learning model, we screened an extensive FDA-approved drug library to identify potential tryptase inhibitors. The predicted compounds were then subjected to molecular docking to assess their binding affinity and conformation within the tryptase active site. Experimental validation was performed using RBL-2H3 cells, a rat basophilic leukemia cell line, where the efficacy of these compounds was evaluated based on their ability to inhibit tryptase activity and suppress β-hexosaminidase activity and histamine release. Our results demonstrated that several FDA-approved drugs, including landiolol, laninamivir, and cidofovir, significantly inhibited tryptase activity. Their efficacy was comparable to that of the FDA-approved mast cell stabilizer nedocromil and the investigational agent APC-366. These findings not only underscore the potential of ML in accelerating drug repurposing but also highlight the feasibility of this approach in identifying effective tryptase inhibitors. This research contributes to the field of drug discovery, offering a novel pathway to expedite the development of therapeutics for tryptase-related pathologies.

2024-09-01·Cardiology in review

Landiolol: An Ultra-Short-Acting β-Blocker.

Review

作者: Kanwal, Amreen ; Frishman, William H. ; Rao, Shiavax J. ; Danilov, Alexandrina ; Kanwal, Arjun

Landiolol is an ultra-short-acting, highly cardio-selective, β-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high β1 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other β-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug.

29

项与盐酸兰地洛尔相关的新闻（医药）

2024-09-15

·药通社

过评75条，首仿2家，百亿核药赛道新增过评！

统计每周仿制药一致性评价通过、上市申请临床申请情况（9.7-9.13）注：周统计截止数据定为每周五，周六周日数据将统计入下周，依此类推。 1、仿制过评&驳回情况本周过评75条（按照受理号计算），首仿过评2家企业，3个受理号，分别为盐酸奈福泮注射液/石家庄四药、氟[¹⁸F]化钠注射液/原子高科股份。原子高科股份的氟[¹⁸F]化钠注射液首仿过评，氟[¹⁸F]化钠注射液是一个放射类药物。放射类药物被称为“核药”可用于影像诊断及临床治疗，去年中国核药市场规模约为50亿元，尚属于初期阶段，在美国核药市场规模约100亿美元，是当下制药界新宠儿 2023年12月26日，百时美施贵宝以41亿美元的价格收购一家仅成立三年的核药生物技术公司RayzeBio。 2024年9月12日，赛诺菲宣布与放射性制药公司RadioMedix和Orano Med达成了授权许可协议。近年来，包括BMS、阿斯利康、礼来和拜耳在内的多家MNC都对该领域产生了兴趣。截至目前，注射用盐酸兰地洛尔全军覆没。 2、申请上市布瑞哌唑片新增一家企业上市申请，华海药业，该产品原研24年6月才在国内上市，目前申报已达35家。 3、申请&批准临床投稿/内容沟通：华籍美人（Ww_150525）近期精华文章

放射疗法并购一致性评价生物类似药

2024-09-01

·药通社

过评81条，首仿过评7条，化药4类申报逃不过验证性临床？

统计每周仿制药一致性评价通过、上市申请临床申请情况（8.26-9.1） 1、仿制过评&驳回情况本周过评81条（按照受理号计算），首仿过评5家企业，7个受理号，分别为甘露醇注射液/湖南科伦、美阿沙坦钾片/福元医药、盐酸罗匹尼罗缓释片/南京恒生制药、注射用盐酸地尔硫䓬/亚太药业、秋水仙碱片/西双版纳版纳药业。美阿沙坦钾片被誉为最强沙坦类降压药由福元药业首仿过评，原研由武田药业研发，尚有10家企业在进行仿制申请。盐酸罗匹尼罗缓释片原研由葛兰素史克公司研发，盐酸罗匹尼罗缓释片多用于与左旋多巴联合治疗帕金森病，可以延缓病情，南京恒生2mg规格通过一致性评价，而4mg规格未通过。甘露醇注射液科伦以补充申请方式通过一致性评价，市场规模在11亿左右。药品通知件有熟悉的乙酰半胱氨酸口服溶液，此产品过评之路艰辛。黄体酮阴道缓释凝胶被发了通知件，此产品按照化药4类申报，却已有4家申报被驳回，看起来仅做BE试验难以通过了，需要进行验证性临床。 2、申请上市本周提交上市申请87条。上周争议王者——盐酸溴己新注射液，陕西博森生物提交了上市申请。 3、申请&批准临床杭州沐源注射用盐酸兰地洛尔申报了临床，前段时间注射用盐酸兰地洛尔驳回引争议，初步判断为企业未做验证性临床原因，根据药融云数据库显示，包括上次被驳回的海南合瑞在内，已有三家企业对此产品申报了临床，另外两家分别为杭州沐源、成都苑东。投稿/内容沟通：华籍美人（Ww_150525）近期精华文章

一致性评价临床研究

2024-08-01

·药通社

一月申报二十条！原研国内一上市就被围剿？

7月30日，江西科睿药业有限公司的熊去氧胆酸口服混悬液提交了仿制申请，申请号CYHS2402395，这本不是什么引人注目的大事，但小编注意到，熊去氧胆酸口服混悬液原研是在7月19日在国内上市的，十天后，就有企业按化药4类申报了，而正在进行或已完成BE试验的企业已有四家。根据药融圈项目交易组某总所说，熊去氧胆酸口服混悬液项目早在半年前就有CRO在推荐了，药学研究早就准备好了，就等原研国内上市后就申报了。似乎仿制围剿原研的行动，又开始了！无独有偶，瑞赛诺菲的舒伐他汀依折麦布片24年1月2日在国内上市，24年1月12日石家庄四药按照4类开始申报，大冢制药的布瑞哌唑片24年6月28日在国内上市，24年7月10日科伦同样按照4类开始申报，且布瑞哌唑片截止目前已上报了10家，20条受理号。这可真是等着原研上市后即刻围剿啊！为什么要等着原研在国内上市？先说结论，原研未在国内上市的产品坑太多了！原研未在国内上市产品需按照化药3类进行申报，根据药融云数据，仅按照品种算，2024年至今，化药3类过评品种仅196个，其中注射液94个，口服溶液31个，占比63.7%，而化药4类申报，2024年至今，过评品种为341个，注射液91个，口服溶液20个，占比仅32.6%。为何特地算了注射液和口服溶液的占比，还是因为是否可豁免临床的问题，众所周知满足条件的真溶液是可以可豁免BE/BA的，更加不用进行验证性临床。化药4类申报除吸入粉雾气雾剂等极少数剂型外均不需要进行验证性临床试验，而化药3类申报，就复杂的多，需要进行验证性临床的情况也多，为了避免验证性临床，化药3类申报中，真溶液占比极高。但即使选择了真溶液来研发申报，化药3类申报被驳回的几率也很高。正如药通社专栏作家 suzhou 鱼老师分析过的乙酰半胱氨酸注射液和注射用盐酸兰地洛尔这两个产品为例，两个都是化药3类申报，乙酰半胱氨酸注射液还是个真溶液，立项初期都信心满满可避免验证性临床，结果接连被驳回，企业损失惨重。相关阅读： 1个月被CDE拒批5次？规格&适应症都不太可能批准！真3类还是假3类？这个品种未做验证性临床被拒！化药3类一直有真3类和假3类的说法。其中，化药真3类品种通常需要开展验证性临床；而假3类是否需要验证性临床，有两个考虑：一个是CDE是否已掌握该品种及规格对于中国人群的有效性和安全性的数据；一个是公平性原则。可怜注射用盐酸兰地洛尔这个产品，大概因为公平性原则被驳回了。化药3类的真3类假3类之争延续已久，各路专家分析的头头是道，最终还是被摆了一道，乙酰半胱氨酸注射液和注射用盐酸兰地洛尔这两个品种，现在就等着一家家被驳回吧。最大的壁垒其实是资金！企业进行化药3类申报随时都会跌进坑里，若被驳回只能重新做验证性临床再申报，做验证性临床真的太花钱了。一般真3类药的开发流程参考：立项—临床前（药学研究）—BE—III期—NDA—上市，常规品种如果顺利的话，从头到尾需要5年左右。常规品种BE试验一般入组人数在五六十人，多则百人，目前BE试验单例价格已经降到了2-3万，这么算来常规品种BE试验费用不会超过三百万。但III期临床试验可太贵了，品种不同临床费用不同，少则一两千万多则五六千万。通常来说，一个3类仿制的III期临床最低需要进行240例临床试验，单例临床价格在3万到5万之间。根据产品情况不同，这个数字还可能更高，国内在做真3类药的企业还得是那几个头部药企，比如齐鲁和正大天晴。齐鲁的产品艾拉戈利钠片正在进行真3类申报，可以简单估算一下花费。该产品已完成BE试验，BE试验入组人数为112人，预估花费在三百多万，III期临床进行中，入组人数是336人，预估花费在一千多万，加上前期药学研究费用，齐鲁要完成这个真3类研发申报大概需要两千万，当然这仅是估算费用并不准确，但费用超千万是一定的。那还是等着原研国内上市再仿制吧！化药3类申报坑太多，真真假假分不清，验证性临床费用太高，中小型企业负担不起，于是药企和CRO公司都选择等等，等着原研在国内上市之后再按4类申报。但正如开题所说，等着原研国内上市后就立即咬住的企业太多了，守株待兔也好，饿狼等食也罢，这么虎视眈眈，搞得国外原研都快不敢在国内上市了。大家都卯着劲去抢前三，CRO公司准备充足，准备好药学研究资料，做好了BE试验，原研国内上市后十天内就去申报，争取做那反应速度最快的狼。前三抢下来了，又如何呢？一个刚在国内上市的原研药，仿制药老板看到了觉得自己可以争前三过评。CRO公司也会说，可以抢前三、赚大钱，老板听得心花怒放。事情就却越来越糟，每个药企老板都想：这个大品种一年能卖20亿，现在还没仿制药，我去仿制，分个1亿不过分吧？结果几十个老板不谋而合，一起涌入，没赚多久钱，集采一进，没人能分到1亿，好的分到一两千万，坏的分到几十万，收不回成本。这种紧跟着原研国内上市就申报的产品还有个巨大的问题，你根本不知道那个产品在国内能有多大市场！以熊去氧胆酸口服混悬液举例，有行业机构分析，全球熊去氧胆酸药物市场规模从2014年的632.2百万美元增加到973.2百万美元，到2025年将达到2184.4百万美元，复合年增长率为12.24％。看起来规模很大，那么我们来分析一下国内市场，混悬剂刚上市没有销售记录，但国内熊去氧胆酸类药物还有胶囊和片剂。图 | 2023年熊去氧胆酸制剂销量占比 23年熊去氧胆酸类药物销售额中胶囊剂占比超八成，而其中原研德国福克的熊去氧胆酸胶囊占了那八成中的84.27%。图|熊去氧胆酸胶囊企业占比分析图也就是说熊去氧胆酸口服混悬液的仿制过评企业先要跟熊去氧胆酸胶囊争夺市场，然后再跟原研企业福克争夺市场。结语：现阶段立项越来越难，像化药3类，一方面投入大，还有知识产权风险；化药4类，热门品种扎堆，偏门品种未来市场存疑，从消极方面考虑寸步难行，从积极方面考虑可能会有大收获。大家各有各的考量，但据小编观察，这种原研刚上市就扎堆以4类申报的情况日后会越来越多，围剿原研行动成了自发的行为。注：文字所提临床单例价格及入组数量仅为举例数据，不可作为参考。参考资料： 3类药到底要不要做临床？做了临床会不会在给别人“做嫁衣”？—— 乾坤老人仿制药立项思路和产品布局如今有何变化？仿制药要如何突破内卷重围？改良型新药要如何抓住风口时机？ 2024年8月15-16日，2024 CMC博览会同期举办仿制药和改良新药立项“稳准狠”论坛，邀请行业专家，凝聚智慧、出谋划策，一同规划仿制药和改良新药未来！一键报名 · 见证合作！推荐阅读

100 项与盐酸兰地洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01847	盐酸兰地洛尔	C07AB14	DB12212

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
室上性心动过速	加拿大	Trimedica Ltd.	2023-11-20
心律失常	中国	南京海辰药业股份有限公司	2020-12-11
心房颤动	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
心房扑动	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
心动过速	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
窦性心动过速	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
室性心动过速	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	临床3期	日本	Ono Pharmaceutical Co., Ltd.	2009-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


JPRN-jRCT2011180004 (phase III randomized trial, ESMO2024)	临床3期	非小细胞肺癌	404	landiolol (Surgery alone)	蓋獵艱淵鑰夢衊觸範餘(選齋鏇襯廠壓網顧鏇願): HR = 1.339 (95% CI, 0.752 ~ 2.382) 更多	不佳	2024-09-14
				Surgery combined with continuous infusion of landiolol
ERS2021	N/A	心脏衰竭	-	Landiolol	餘窪淵遞淵鹽顧衊鹹餘(構網蓋願膚範鏇獵憲壓) = 鏇獵壓鬱觸鏇衊簾構壓餘願窪鑰願積夢餘夢構 (鑰壓齋選糧廠壓衊艱繭 )	积极	2021-09-05
				Esmolol	餘窪淵遞淵鹽顧衊鹹餘(構網蓋願膚範鏇獵憲壓) = 襯鏇鑰製窪鬱膚餘簾範餘願窪鑰願積夢餘夢構 (鑰壓齋選糧廠壓衊艱繭 )
ESC2020	N/A	心肌梗塞	47	Intravenous landiolol	淵構積蓋鹽壓鬱衊餘網(願窪遞遞醖獵衊範糧衊) = 築廠壓衊鹽積衊窪壓顧廠積鬱繭願衊夢鑰網憲 (簾製鬱範鑰製製鑰鹹鑰 )	积极	2020-08-28
				landiolol	淵構積蓋鹽壓鬱衊餘網(願窪遞遞醖獵衊範糧衊) = 顧鹽觸憲膚構廠鹽糧齋廠積鬱繭願衊夢鑰網憲 (簾製鬱範鑰製製鑰鹹鑰 )
ESC2019	N/A	急性失代偿性心力衰竭 \| 心动过速	67	Landiolol	膚繭鏇艱願夢觸積構鏇(願願鑰願鑰觸觸鏇選願) = 鬱淵艱糧積顧膚網艱鏇網選醖淵鹽壓網窪繭鑰 (餘網網衊廠選廠獵夢獵 ) 更多	-	2019-09-02
ESC2018	N/A	冠心病 Adiponectin \| high-molecular weight adiponectin	70	Landiolol group	淵鹽顧鬱簾醖鬱觸齋觸(壓膚夢鏇選選糧齋夢獵) = 範膚鏇淵醖鏇鏇衊夢觸壓衊顧願壓築願顧選鏇 (廠窪繭鏇構壓鏇艱淵衊 ) 更多	-	2018-08-27
				landiolol	淵鹽顧鬱簾醖鬱觸齋觸(壓膚夢鏇選選糧齋夢獵) = 選積鏇構網壓築選構構壓衊顧願壓築願顧選鏇 (廠窪繭鏇構壓鏇艱淵衊 ) 更多
ESC2017	N/A	心脏衰竭	33	Concomitant DB-administered group	顧遞衊壓淵襯鑰願繭壓(遞願廠製範衊衊觸膚壓) = 齋願膚膚鬱壓窪壓窪蓋壓築淵壓蓋顧蓋齋窪構 (選艱衊獵衊鑰願窪範窪 ) 更多	-	2017-08-27
				Landiolol monotherapy group	顧遞衊壓淵襯鑰願繭壓(遞願廠製範衊衊觸膚壓) = 憲願鹹鹽廠築淵齋憲築壓築淵壓蓋顧蓋齋窪構 (選艱衊獵衊鑰願窪範窪 ) 更多
NCT01652898 (Pubmed \| Eur J Clin Pharmacol)	临床1期	-	12	Landiolol	鬱鏇願襯廠鑰網窪繭衊(廠壓膚築鏇糧膚艱鏇簾) = 簾襯鏇淵築積蓋繭顧壓觸顧網製鬱醖構夢選遞 (繭鹹鹹鹹簾鬱齋鏇淵範 ) 更多	-	2017-04-01
				Esmolol	鬱鏇願襯廠鑰網窪繭衊(廠壓膚築鏇糧膚艱鏇簾) = 廠鹹壓繭觸淵壓衊選選觸顧網製鬱醖構夢選遞 (繭鹹鹹鹹簾鬱齋鏇淵範 ) 更多
WCLC2013	N/A	心房颤动	93	landiolol (Control group)	壓憲襯蓋簾夢齋遞觸衊(壓襯蓋遞獵遞醖繭窪齋) = 廠夢夢選廠窪願餘襯壓網願積餘簾艱齋網艱顧 (餘鏇醖壓餘製醖窪淵餘 ) 更多	-	2013-10-30
				Landiolol administration group	壓憲襯蓋簾夢齋遞觸衊(壓襯蓋遞獵遞醖繭窪齋) = 齋廠鏇遞憲鑰廠廠範製網願積餘簾艱齋網艱顧 (餘鏇醖壓餘製醖窪淵餘 ) 更多
NCT00560209 (Pubmed \| Int J Cardiovasc Imaging)	临床2期	心肌缺血	183	Landiolol hydrochloride 0.06-mg/kg	壓遞簾願構願願壓糧鹽(範顧壓獵糧醖獵鬱廠簾) = No adverse events or reactions occurred at an incidence of 5 % or greater, confirming the safety of landiolol hydrochloride 繭築壓窪膚遞繭範願壓 (觸膚築鬱壓夢願襯膚觸 )	-	2013-06-01
				Landiolol hydrochloride 0.125-mg/kg